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Background: Safety of tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) has been studied more extensively
among HIV-infected patients than among HIV-uninfected people. Using data from a pre-exposure trial – FEM-PrEP –,
we determined the cumulative probabilities of grade 1+ ALT, AST and creatinine and grade 2+ phosphorus toxicities;
ALT/AST toxicities by baseline hepatitis B status; and change in mean creatinine, phosphorus, ALT and AST levels
controlling for TDF-FTC adherence.
Methods and findings: FEM-PrEP was a randomized, blinded, placebo-controlled trial of daily TDF-FTC among women
in Africa. Enrolled women were in general good health, HIV antibody negative, 18 to 35 years old, hepatitis B surface
antigen negative, and had normal hepatic and renal function at baseline. AST, ALT, phosphorus and serum creatinine
were measured regularly throughout the trial. TDF-FTC concentrations were measured to assess adherence to TDF-FTC.
The cumulative probabilities of grade 1+ creatininemia and grade 2+ phosphatemia toxicities were not statistically
different between TDF-FTC and placebo arms. The cumulative probabilities of grade 1+ ALT and AST toxicities were
higher among participants in the TDF-FTC arm than in the placebo arm (p = 0.03 for both). The proportions of
grade 1+ and grade 2+ ALT or AST toxicities were significantly higher in participants who were hepatitis B virus surface
antibody (HBsAb) positive than in those who were HBsAb-negative. Women with good adherence had higher
mean change from baseline to week 4 in their AST levels (2.90 (0.37, 5.42); p = 0.025) than women with less than
good adherence.
Conclusions: We did not observe a significant relationship between randomization to TDF-FTC and creatinine or
phosphorus toxicities. Women randomized to TDF-FTC had higher rates of mild to moderate ALT/AST toxicities,
especially women with prior hepatitis B virus exposure. We also observed a significant increase in AST from baseline to
week 4 among women who had higher adherence to TDF-FTC during that interval.
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Decades into HIV prevention research, there is strong
evidence that the use of antiretrovirals (ARV) as pre-
exposure prophylaxis (PrEP) significantly reduces the
risk of acquiring HIV infection in men and women
[1-5]. While the safety of tenofovir disoproxil fumarate
(300 mg)/emtricitabine (200 mg) (TDF-FTC) has been
extensively studied among HIV-infected patients, limited
data are available among HIV-uninfected people [6-10].
Here we report on the hepatic and renal safety of TDF-
FTC in a pre-exposure prophylaxis clinical trial – FEM-
PrEP – among HIV negative women in Africa [11].
FEM-PrEP was a randomized, double-blind, placebo-
controlled trial of once-daily oral TDF-FTC in Africa
among women at high risk of acquiring HIV via sexual
intercourse. The study was stopped early due to futility,
likely due to low adherence to the daily oral regimen by
study participants [11].
The primary safety endpoints included grade 2+ cre-
atinine toxicities and grade 3+ alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and phos-
phorus based on the U.S. NIH, NIAID Division of AIDS
(DAIDS) grading table and on local normal ranges [12].
Secondary safety outcomes included grade 1+ ALT, AST
and creatinine toxicities and grade 2+ phosphorus. Due
to overall low TDF-FTC exposure in the study popula-
tion, we also conducted exploratory analyses controlling
for actual TDF drug levels [11,13].
We report on the cumulative probabilities of grade 1+
ALT, AST and creatinine toxicities and grade 2+ phos-
phorus; ALT/AST toxicities by baseline hepatitis B status;
and change in means of creatinine, phosphorus, ALT and
AST levels controlling for TDF-FTC adherence.Methods
Ethics statement
The trial and informed consent forms were approved by
all applicable ethics and regulatory committees: The Pro-
tection of Human Subjects Committee of FHI360, the US
Food and Drug Administration, the ethics committee (EC)
of the University Hospital of Antwerp, the Institutional
Review Board of ITM, the Kenyatta National Hospital/
University of Nairobi Ethics and Research Committee, the
Republic of Kenya Ministry of Health (MoH- Pharmacy &
Poisons Board), Kilimanjaro Christian Medical Center
Research EC of Tanzania, National Institute for Medical
Research of Tanzania, London School of Hygiene and
Tropical Medicine EC, Tanzania Food and Drugs Authority,
Medunsa Campus Research and EC of South Africa,
University of the Free State EC and Medicines Control
Council of South Africa. Written informed consent was
obtained from all participants prior to conducting any
study procedures.Context: FEM-PrEP study
The details of the FEM-PrEP study have been described
elsewhere [11]. The trial was approved by all applicable
ethical and regulatory committees and participants pro-
vided written informed consent before any procedures
were performed. Women were recruited from Pretoria and
Bloemfontein, South Africa; Bondo, Kenya; and Arusha,
Tanzania. Eligibility criteria required that women be HIV
antibody negative, 18 to 35 years old, in general good
health, hepatitis B virus surface antigen (HBsAg) ne-
gative and have no evidence of abnormal hepatic or renal
function at baseline (i.e., serum creatinine < 1.5 mg/dl, cre-
atinine clearance ≥ 60 ml/min estimated by the Cockcroft-
Gault method, ALT and AST <2× local upper limit of
normal [ULN] and serum phosphorus levels above
the lower limit of the normal range and below DAIDS
grade 3). Participants attended study visits at screening,
enrollment (2–4 weeks later), and at 4-week intervals
thereafter for up to 60 weeks (52 weeks on product
followed by eight weeks off product). Plasma and upper
layer packed cell (ULPC) aliquots were stored for TDF-
FTC concentration testing at monthly visits; hepatic and
renal (AST, ALT, creatinine and phosphorus) parameters
were evaluated at weeks 4, 12, 24, 36, 52, 56 and when
clinically indicated [13].
Laboratory analysis
AST, ALT, phosphorus and serum creatinine assays were
performed according to manufacturer procedures. Sam-
ples were processed within two hours after collection. The
VITROS DT II instrument (Ortho-Clinical Diagnostics,
Inc., Johnson & Johnson, Buckinghamshire, UK) was used
in Kenya until May 2010, thereafter the VITROS 250
(Ortho-Clinical Diagnostics, Inc., Johnson & Johnson,
Buckinghamshire, UK), the CX5 Beckman Chemistry
Analyzer (Beckman Coulter, Inc, Fullerton, CA, USA) was
used at both South African sites and the Cobas Integra 400
Plus (Roche Diagnostics GmbH, Mannheim, Germany)
was used at the Tanzanian site.
Site-specific laboratory normal ranges (LNR) were
used due to unknown population similarities/differences
and different instrumentation used across sites. Manu-
facturer recommended, or nationally/regionally estab-
lished LNRs were used during the first two to three
months of the trial while site-specific LNRs were deve-
loped. The local LNR was identified and verified, using
Sigma Diagnostic guidelines, by the central laboratory
(Institute of Tropical Medicine, Antwerp, Belgium) [14].
Details of the verification process will be described in a
separate manuscript. Locally verified ranges were used
for final grading of all biochemistry toxicities in Kenya
and South Africa. In Tanzania, due to the delay in study
initiation and early closure of the trial, local LNR were
not verified; manufacturer LNRs were used instead.
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good clinical laboratory practice and technical training
for all protocol-required laboratory tests, and conducted
quality assurance activities including co-development of
site standard operating procedures (SOPs) and analytical
plans, assay and equipment validation, external quality
assessment (EQA) schemes, and equipment calibration
and maintenance. In addition, central lab staff conducted,
at a minimum, annual site visits to verify proper conduct
of laboratory procedures and review source data.
TDF-FTC concentration analysis on stored samples was
conducted at the University of North Carolina at Chapel
Hill. Tenofovir (TFV) was measured in plasma and teno-
fovir diphosphate (TFV-DP) in ULPC. Laboratory proce-
dures for TDF-FTC concentration analysis were published
previously [11,13]. Adherence was qualitatively classified
on a 6-point scale based on drug concentration data, with
the top two adherence scores being “good” and “excellent”
(good = plasma TFV levels >10 ng/ml and ULPC intracel-
lular TFV-DP between 100,000-1,000,000 femtomoles/
million cells, excellent = plasma TFV levels >10 ng/ml and
ULPC intracellular TFV-DP between >1,000,000 femto-
moles/million cells) [13].
Management of toxicity and study product interruptions
Protocol-defined toxicities were defined and managed
according to clinical assessment, grade and relatedness
to the study product as assessed by study clinicians [12].
Study product was temporarily or permanently with-
drawn as per protocol-described criteria.
Hepatotoxicity grade 2 was defined as 2.6 -5.0 × upper
limit of normal (ULN), if determined to be related to the
study product, the study product was interrupted and
was restarted only if AST/ALT decreased to ≤ grade 1.
Hepatotoxicity grade 3 was defined as 5.1 - 10.0 × ULN
and study product was interrupted independent of re-
latedness assessment. Study product was restarted if AST/
ALT decreased to ≤ grade 1. Hepatotoxicity grade 4 was
defined as > 10.0 × ULN and study product was perma-
nently withdrawn independent of relatedness.
Creatininemia grade 1 was defined as 1.1 -1.3 × ULN
and grade 2 as 1.4 -1.8 × ULN; study product was inter-
rupted for both grades regardless of the relatedness to
study product use and was restarted if creatininemia de-
creased to < grade 1 or < 1.3× baseline. Study product
was permanently withdrawn for creatininemia grade 2
determined to be related to the study product, and for
any creatininemia grade 3 (>1.8 × ULN)
Study product was also permanently withdrawn when
there was hypophosphatemia associated with elevated
creatininemia, low creatinine clearance or proteinuria. In
case of pregnancy, study product was interrupted and re-
sumption allowed after delivery and completion of breast-
feeding or with evidence of pregnancy loss/termination).Study product was immediately discontinued in partici-
pants who HIV seroconverted.
Sample selection
The analysis population consisted of all women rando-
mized into the trial, excluding participants who never re-
ceived study product, returned all product unused, or
never returned for a follow-up visit. TDF-FTC concen-
tration data were available for a random sub-cohort of
150 participants assigned TDF-FTC, (50 from each of
the three sites where HIV infections took place, i.e.,
Bloemfontein, Pretoria and Bondo).
Statistical analyses
Cumulative probabilities of grade 1+ creatinine, ALT and
AST and grade 2+ phosphorus were plotted with data
pooled across sites by treatment group over time using
Kaplan-Meier methods. In addition, the number and of
percentage of women experiencing toxicities by grade
were summarized by baseline HBsAg status and treat-
ment group; fisher exact tests were used to compare dif-
ferences between groups.
For the random sub-cohort of 150 women in the TDF-
FTC arm, we further assessed the association between ad-
herence to TDF-FTC and change from baseline to week 4
in creatinine, phosphorus, ALT, and AST levels using
generalized linear models, with adjustment for baseline
level, age, body mass index, oral contraceptive (OC) use at
enrollment and study site. A similar analysis was done for
change from last visit on-product and first visit after pro-
duct use ceased (at study exit or earlier product with-
drawal). SAS 9.3 (SAS Institute, Cary, NC) was used for
all analyses; statistical significance was defined as p ≤ 0.05.
Results
Characteristics of enrolled population
The analysis included a total of 2,058 women who were
enrolled during June 2009 to April 2011. There were 701
and 707 person-years of follow up in the TDF-FTC and
placebo arms respectively. Demographic characteristics,
medical history and self-reported sexual behavior at
baseline have been reported elsewhere and were ge-
nerally similar between both groups [11]. At enrolment
20.8% and 21.4% of participants were hepatitis B surface
antibody (HBsAb) positive in the TDF-FTC and placebo
arms respectively.
Kidney toxicity
The cumulative probabilities of grade 1+ creatinine or
grade 2+ phosphatemia toxicities were higher in the
TDF-FTC arm, although neither of these differences
were statistically significant (Figures 1 and 2).
Six participants developed grade 2+ creatininemia:
four (0.4%) in the TDF-FTC arm and two (0.2%) in the
Figure 1 Cumulative probability of grade 1+ creatinine toxicity,
with number of participants at risk at the start of 4-week
intervals (log-rank test, stratified on site, p = 0.128).
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comparable to the average baseline creatininemia at
their respective sites. Among the four participants in the
TDF-FTC arm, the grade 2+ creatininemia resolved after
1, 2, 16 and 28 weeks respectively; among the two in the
placebo arm, one resolved after 6 weeks and decreased
to a grade 1 for 10 weeks in the second participant. The
latter participant was referred to a nephrologist at the
closing of the trial; she later self-reported that her cre-
atinine returned to normal, though results could not be
validated by the study team.
None of the six participants with grade 2+ creatininemia
reported taking concomitant medication at the time of the
event. TDF-FTC drug concentration data were available
for the four participants in the TDF-FTC arm: one was
classified as having excellent adherence, two as having
good adherence, and one as not adherent in the interval
prior to the event.Figure 2 Cumulative probability of grade 2+ phosphorus
toxicity, with number of participants at risk at the start of
4-week intervals (log-rank test, stratified on site, p = 0.621).Hepatic toxicity
The cumulative probabilities of grade 1+ ALT and AST
toxicities were higher among participants in the TDF-
FTC arm than in the placebo arm (p = 0.03 for both)
(see Figures 3 and 4).
Sixteen participants developed grade 3+ ALT and/or
AST toxicities: eight in the TDF-FTC arm and eight in
the placebo arm. Baseline AST/ALT levels among these
participants were comparable to the average ALT/AST
in their respective sites. In three of these 16 participants,
the grade 3+ ALT/AST occurred at the time of HIV
seroconversion (one in the TDF-FTC arm and two in
the placebo arm), and 11 of the 16 (six in the TDF-FTC
arm and five in the placebo arm) events occurred in par-
ticipants who had received the hepatitis B vaccine. Six
participants (two in the TDF-FTC arm and four in the
placebo arm) with grade 3+ ALT/AST toxicities reported
taking a concomitant medication at the time of the
event; medications included acetaminophen, ibuprofen,
diclofenac and metronidazole. All grade 3+ ALT/AST
toxicities were resolved between two and eight weeks
without any difference in time to resolution between
TDF-FTC and placebo arms. One participant (in the pla-
cebo arm) with grade 3+ ALT at week 12 never returned
to the study clinic despite intense tracing efforts. Drug
level data were available for seven participants in the
TDF-FTC arm with grade 3+ ALT/AST: two were clas-
sified as having excellent adherence, one as having good
adherence and four as non-adherent in the interval be-
fore the event.
At one site – Bondo – the proportion of grade 2+ AST
toxicities was significantly higher in the TDF-FTC arm
(5.0%) than in the placebo arm (1.9%) (p = 0.02). Also,
overall, Bondo observed higher proportions of grade 1+
AST toxicities (43.1% in TDF-FTC arm vs. 36.4% in
placebo arm) compared to Bloemfontein (5.7% vs. 3.7%Figure 3 Cumulative probability of grade 1+ AST toxicity, with
number of participants at risk at the start of 4-week intervals
(log-rank test, stratified on site, p = 0.025).
Figure 4 Cumulative probability of grade 1+ AST toxicity, with
number of participants at risk at the start of 4-week intervals
(log-rank test, stratified on site, p = 0.025).
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Arusha (0% vs. 3.6% respectively). At baseline, Bondo par-
ticipants had a higher exposure to hepatitis B.
In the TDF-FTC arm, the proportions of grade 1+ and
grade 2+ ALT or AST toxicities were significantly higher
in participants who were HBsAb positive than in those
who were HBsAb negative; for grade 1+, 31.6 vs. 22.4%
respectively, p < 0.007 and for grade 2+, 5.6 vs. 2.6% re-
spectively, p < 0.047 (Table 1). In the placebo arm, only
the proportion of grade1+ ALT or AST toxicities was
significantly more frequent in HBsAb positive parti-
cipants vs. HBsAb negative participants; 29.5 vs. 17.1%,
p < 0.001 (Table 2).
TDF-FTC concentrations and observed kidney or hepatic
toxicities
TDF-FTC concentration data from a sub-cohort of 150













Grade 1 or higher 238 180 22.4 449.4 40.05
Grade 2 or higher 24 21 2.6 525.0 4.00
Grade 3 or higher 6 6 0.7 532.6 1.13
Grade 4 1 1 0.1 535.8 0.19
PHO G2+ and creatininemia
Grade 1 or higher 11 10 1.2 532.5 1.88
Grade 2 or higher 0 0 0.0 535.8 0.00
Grade 3 or higher 0 0 0.0 535.8 0.00
Grade 4 0 0 0.0 535.8 0.00
#Difference in the proportions of participants experiencing toxicities.study drug, making it impossible to assess the impact of
continuous exposure over longer periods and liver/
kidney function. However, the percentage of women
with evidence of good adherence in their first four weeks
of participation (~40%) was sufficient to assess the im-
pact of short-term drug use. We observed that women
with evidence of good adherence had higher mean
change from baseline to week 4 in their AST levels (2.90
(0.37, 5.42); p = 0.025) as compared to women with less
than good adherence. However, corresponding changes
in ALT (1.54 (−1.44, 4.52); p = 0.31), creatinine (0.19
(−2.60, 2.98); p = 0.89) and phosphorus (0.02 (−0.04,
0.08); p = 0.53) were not statistically significant. We did
not observe an association between adherence to TDF-
FTC and change in ALT, AST, creatinine or phosphorus
levels between the final drug-use interval and four weeks
after product withdrawal.
Discussion
In this article we report on change (grade 1+) in renal
and hepatic function among African women who were
assigned to the active TDF-FTC arm of a randomized,
placebo-controlled clinical trial of HIV pre-exposure
prophylaxis. While we did not find significant differences
in renal functions, we observed a significant increase in
the cumulative probabilities of grade 1+ hepatotoxicity,
as measured by ALT and AST, among women assigned
TDF-FTC.
Our safety findings are comparable to other PrEP stu-
dies which also did not observe more frequent renal
toxicity in the active arm than in the placebo one [2,5,15].
With regard to hepatic toxicity, we observed more fre-
quent elevated ALT or AST in participants with previous
exposure to hepatitis B virus; which is consistent with
the finding in the Bondo site of significantly more grade














91 68 31.6 123.4 55.09 9.2 (0.007)
12 12 5.6 152.0 7.90 3.0 (0.047)
2 2 0.9 156.6 1.28 0.2 (0.678)
1 1 0.5 157.2 0.64 0.3 (0.378)
2 2 0.9 156.4 1.28 −0.3 (1.0000)
1 1 0.5 156.7 0.64 0.5 (0.2110)
1 1 0.5 156.7 0.64 0.5 (0.2110)
0 0 0.0 157.4 0.00 0 (-)
Table 2 Laboratory toxicities during scheduled follow-up in the placebo arm by previous exposure to HBV
























Grade 1 or higher 163 138 17.1 476.1 28.99 79 66 29.5 138.4 47.70 12.4 (0.0001)
Grade 2 or higher 20 19 2.4 527.6 3.60 4 4 1.8 165.0 2.42 −0.6 (0.7996)
Grade 3 or higher 8 8 1.0 531.3 1.51 0 0 0.0 166.4 0.00 −1.0 (0.2126)
Grade 4 2 2 0.2 533.0 0.38 0 0 0.0 166.4 0.00 −0.2 (1.0000)
PHO G2+ and creatininemia
Grade 1 or higher 3 2 0.2 532.6 0.38 0 0 0.0 166.2 0.00 −0.2 (1.0000)
Grade 2 or higher 0 0 0.0 533.3 0.00 0 0 0.0 166.2 0.00 0 (-)
Grade 3 or higher 0 0 0.0 533.3 0.00 0 0 0.0 166.2 0.00 0 (-)
Grade 4 0 0 0.0 533.3 0.00 0 0 0.0 166.2 0.00 0 (-)
#Difference in the proportions of participants experiencing toxicities.
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in Bloemfontein, Pretoria, and Arusha, respectively).
Additional observations are needed to confirm this pre-
liminary finding, particularly in settings where hepatitis
B virus prevalence is high and TDF-FTC will be con-
sidered for PrEP. Drug-induced liver injury (DILI) is a
possible explanation of our findings. DILI has been de-
scribed in patients with pre-existing hepatic illness like
non-alcoholic fatty liver disease (NAFLD), hepatitis C
virus related chronic hepatitis [16,17]. Our study was
not designed to verify association between our observa-
tions and any of these specific pre-existing conditions.
None of the laboratory toxicities observed was accom-
panied by specific renal or hepatic clinical symptoms.
The lack of clinical symptoms is likely due to the rela-
tively moderate level of the toxicities observed, frequent
testing and subsequent interruption or withdrawal of the
study product.
Although these data indicate that the use of TDF-FTC
as PrEP is safe with regard to kidney and hepatic toxicity,
the results must be considered in light of overall low ad-
herence to study product. Further, our study used the
serum creatinine level and the Cockcroft-Gault formula to
assess glomerular filtration and phosphatemia to assess
proximal tubular function. Some studies have suggested
that more sophisticated formulas – e.g. four-variable
Modification of Diet in Renal Disease formula (MRDR
equation) [18,19] – and multifactor algorithms are more
accurate in assessing glomerular filtration and proxi-
mal tubular function. In a study comparing tenofovir-
containing to tenofovir-sparing HAART in patients living
with HIV, Horberg et al., using the MDRD equation,
found that the tenofovir-exposed group had a statistically
greater percentage of patients with glomerular filtration
decline but not creatininemia rising to greater than2.0 mg/dL [10]. HIV/AIDS patients treated with ARVs can
develop kidney and/or liver toxicity for many other rea-
sons than the use of TDF-FTC: HIV infection itself, other
ARVs or any other medication to manage their HIV/AIDS
condition. In our study, participants were HIV uninfected
and healthy at baseline and took limited concomitant
medication [20,21].
Our analysis and conclusions are also limited by
short overall TDF-FTC exposure (i.e., follow-up was < =
52 weeks); studies and expert opinions suggest that kid-
ney toxicities may increase over time with prolonged ex-
posure to TDF-FTC [10,22].
The main limitation of our study is the limited adhe-
rence of participants to the study drug; only about 40%
exhibited good adherence during any given test interval,
and far fewer exhibited consistently good adherence over
the course of their participation [11]. Nonetheless, in the
TDF-FTC arm we observed higher cumulative proba-
bilities of grade 1+ of ALT/AST and a higher proportion
of participants with grade 2+ ALT/AST when previously
exposed to HBV.
Conclusion
In our study population of healthy young African
women, we did not observe a significant relationship
between randomization to TDF-FTC and creatinine or
phosphorus toxicities although we were limited in our
ability to adequately assess these relationships due to
overall low adherence to the study product. Women ran-
domized to TDF-FTC had higher rates of mild to mo-
derate ALT/AST toxicities, especially women with prior
hepatitis B virus exposure. We also observed a signifi-
cant increase from baseline to week four in AST values
among women who were highly adherent to TDF-FTC
during that interval.
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